The tablets, used to treat a potassium deficiency, are a generic version of K Dur tablets produced by Merck Sharp & Dohm, a subsidiary of Kenilworth, N.J.-based Merck.
The K Dur tablets reported annual sales of $283 million for the 12-month period ending May 2016, according to IMS Health sales data.
India-based Glenmark Pharmaceuticals currently has 117 products authorized for distribution in the U.S. and 61 products pending approval from the FDA.
More articles on the drug market:
Patients in Texas and Florida gain easier access to opioid-overdose antidote naloxone
Eli Lily exceeds 2Q expectations thanks to new drug sales
Sen. Bernie Sanders’ DNC speech tackles high prescription drug costs: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
